Artal Group’s Cellectis CLLS Stock Holding History

Artal Group’s Portfolio CLLS Stock Details CLLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-100,000	Closed	-$2.92M	–	119
2017 Q4	$2.92M	Hold	100,000	–	–	0.04%	88
2017 Q3	$2.85M	Hold	100,000	–	–	0.05%	82
2017 Q2	$2.58M	Sell	100,000 -50,000	-33%	-$1.19M	0.05%	88
2017 Q1	$3.6M	Hold	150,000	–	–	0.08%	71
2016 Q4	$2.54M	Hold	150,000	–	–	0.06%	72
2016 Q3	$3.61M	Sell	150,000 -60,000	-29%	-$1.57M	0.07%	65
2016 Q2	$5.58M	Hold	210,000	–	–	0.12%	40
2016 Q1	$5.78M	Hold	210,000	–	–	0.11%	40
2015 Q4	$6.52M	Buy	210,000 +85,000	+68%	+$2.58M	0.12%	57
2015 Q3	$3.29M	Hold	125,000	–	–	0.07%	63
2015 Q2	$4.51M	Buy	125,000 +25,000	+25%	+$878K	0.19%	58
2015 Q1	$3.46M	Buy	+100,000	New	+$3.63M	0.16%	64

Other funds holding CLLS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Ascend Capital Orinda, California $1.99B AUM 10.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Artal Group's CLLS Position: Q1 2018 in Review

Artal Group sold out of Cellectis (CLLS) in Q1 2018, closing a stake of 100,000 shares — an estimated $2.92M sold.

Artal Group first reported a position in CLLS in Q1 2015 and held it in 12 quarters. The position peaked at $6.52M in Q4 2015. 69 funds tracked by Wall St. Rank hold CLLS as of Q1 2018.

Artal Group reported no remaining Cellectis position as of Q1 2018 after selling out during the quarter.
Artal Group sold 100,000 Cellectis shares in Q1 2018, an estimated $2.92M.
Artal Group first reported a position in Cellectis in Q1 2015 and held it in 12 quarters.
Artal Group's Cellectis position peaked at $6.52M in Q4 2015.
69 funds tracked by Wall St. Rank held Cellectis as of Q1 2018.

Based on Artal Group's 13F filing for Q1 2018, filed 10 May 2018.